Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recursion Pharmaceuticals
Biotech
Rallybio shifts gears, cashing out of Recursion pact
Rallybio has swerved away from its Recursion pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway.
Nick Paul Taylor
Jul 8, 2025 8:59am
Recursion lays off 20% of staff in wake of pipeline cutbacks
Jun 10, 2025 9:25am
Recursion streamlines pipeline following merger with Exscientia
May 5, 2025 11:00am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Altitude sources funding for biotechs concerned about NIH grants
Feb 19, 2025 1:00pm
Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival's data
Nov 13, 2024 8:15am